Pathology: la/mBC - HR positive - L1 - PIK3CA mutant; la/mBC - HR-positive - 1st line (L1); mBC - TNBC - L1 - all population; mBC - Triple negative (TNBC) - 1st Line (L1);
| la/mBC - HR positive - L1 - PIK3CA mutant | la/mBC - HR-positive - 1st line (L1) | mBC - TNBC - L1 - all population | mBC - Triple negative (TNBC) - 1st Line (L1) | |||
| IPATunity130, 2022 | BEECH, 2019 | PAKT (all population), 2020 | LOTUS, 2017 | PAKT (PIK3CA/AKT1/PTEN-altered), 2020 | ||
| capivasertib plus paclitaxel | 3 | T1 | T1 | T1 | ||
| ipatasertib plus paclitaxel | 2 | T1 | T1 | |||
| paclitaxel | 0 | T0 | T0 | |||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | ||